论文部分内容阅读
目的:研究罗格列酮(rosiglitazone,ROZ)对裸鼠体内人肝癌SMMC7721细胞增殖的影响。方法:建立人肝癌裸鼠移植瘤模型,实验动物分为罗格列酮治疗组及对照组。观察罗格列酮对移植瘤体积和重量的变化,采用光镜观察移植瘤细胞形态学变化,流式细胞术检测移植瘤细胞周期分布,免疫组织化学和蛋白印迹检测瘤组织内增殖细胞核抗原(proliferating cell nuclearantigen,PCNA)蛋白表达变化。结果:罗格列酮在体内能明显抑制移植瘤的生长,抑瘤率为50.81%;组织学显示治疗组瘤细胞异型性降低,核质比下降;流式细胞术分析显示,对照组移植瘤细胞处于G2/M期细胞为13.1%,与对照组比较,治疗组处于G2/M期细胞显著增多(29.1%)。免疫组织化学和蛋白印迹检测均显示检测显示,经罗格列酮处理后,裸鼠移植瘤组织PCNA蛋白表达明显下调(P<0.05)。结论:罗格列酮可体内抑制人肝癌SMMC7721细胞增殖,并使癌细胞阻滞于G2/M期。
Objective: To study the effect of rosiglitazone (ROZ) on the proliferation of human hepatoma SMMC7721 cells in nude mice. Methods: The human hepatocellular carcinoma xenograft model was established. The experimental animals were divided into rosiglitazone treatment group and control group. The changes of the volume and weight of the xenografts were observed. Morphological changes of the xenografts were observed with light microscope. The cell cycle distribution of the xenografts was detected by flow cytometry. The expression of proliferating cell nuclear antigen (PCNA) in the tumor tissue was detected by immunohistochemistry and Western blotting proliferating cell nuclearantigen (PCNA) protein expression changes. Results: Rosiglitazone significantly inhibited the growth of xenografts in vivo, with a tumor inhibition rate of 50.81%. Histology showed that the atypia of tumor cells decreased and the ratio of nucleus to cytoplasm decreased in the treatment group. Flow cytometry analysis showed that the transplanted tumor Cells in G2 / M phase were 13.1%, compared with the control group, the treatment group in G2 / M phase cells increased significantly (29.1%). Immunohistochemistry and Western blotting showed that the expression of PCNA protein in nude mice xenografts was significantly down-regulated after rosiglitazone treatment (P <0.05). CONCLUSION: Rosiglitazone inhibits the proliferation of human hepatocellular carcinoma SMMC7721 cells in vivo and arrests the cancer cells in G2 / M phase.